France Influenza Vaccine Market Size & Outlook, 2024-2030
- Pharmaceuticals
- Vaccines
- Influenza Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the influenza vaccine market
France influenza vaccine market highlights
- The France influenza vaccine market generated a revenue of USD 229.5 million in 2023 and is expected to reach USD 362.3 million by 2030.
- The France market is expected to grow at a CAGR of 6.9% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 229.5 million |
| Market revenue in 2030 | USD 362.3 million |
| Growth rate | 6.9% (CAGR from 2024 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, France accounted for 2.9% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- Denmark is the fastest growing regional market in Europe and is projected to reach USD 31.6 million by 2030.
In October 2020, France launched a flu vaccine campaign to spread awareness regarding flu and influenza in the country. Such awareness programs help people identify symptoms, thereby creating more demand for influenza vaccines. France has a blend of several regional and multinational players offering influenza vaccines.
Thus, several strategic initiatives undertaken by leading participants are likely to fuel market expansion. For instance, in November 2019, the U.S. FDA approved a supplemental Biologics License Applications for Fluzone, a quadrivalent vaccine for adults aged more than 65. Fluzone is a high-dose vaccine containing strains of both influenza A and B.
Moreover, positive results from clinical studies of vaccine candidates are likely to support the market. For instance, in October 2021, Sanofi announced positive results from the first study of a COVID-19 mRNA booster with high-dose influenza vaccine.
No credit card required*
Publish Date: Dec 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Viatris Inc | View profile | 38,000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | www.viatris.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| Emergent BioSolutions Inc | View profile | 1,600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | www.emergentbiosolutions.com |
| Vaxess Technologies | View profile | 51-100 | Cambridge, Massachusetts, United States, North America | www.vaxess.com |
| Osivax | View profile | 11-50 | Lyon, Rhone-Alpes, France, Europe | www.osivax.com/ |
France Influenza Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Influenza Vaccine Market Outlook will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 96.99% in 2023.
Horizon Databook has segmented the France influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
In October 2020, France launched a flu vaccine campaign to spread awareness regarding flu and influenza in the country. Such awareness programs help people identify symptoms, thereby creating more demand for influenza vaccines. France has a blend of several regional and multinational players offering influenza vaccines.
Thus, several strategic initiatives undertaken by leading participants are likely to fuel market expansion. For instance, in November 2019, the U.S. FDA approved a supplemental Biologics License Applications for Fluzone, a quadrivalent vaccine for adults aged more than 65. Fluzone is a high-dose vaccine containing strains of both influenza A and B.
Moreover, positive results from clinical studies of vaccine candidates are likely to support the market. For instance, in October 2021, Sanofi announced positive results from the first study of a COVID-19 mRNA booster with high-dose influenza vaccine.
- France Influenza Vaccine Market Vaccine Type Outlook (Revenue, USD Million , 2018-2030)
- Inactivated
- Live Attenuated
- France Influenza Vaccine Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Quadrivalent
- Trivalent
- France Influenza Vaccine Market Age Group Outlook (Revenue, USD Million , 2018-2030)
- Pediatric
- Adult
- France Influenza Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2018-2030)
- Injection
- Nasal Spray
- France Influenza Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Pharmacy
- Government & Institutional supply
- Other Distribution Channels
Reasons to subscribe to Influenza Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Influenza Vaccine Market Outlook databook
- Our clientele includes a mix of Influenza Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France Influenza Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into France Influenza Vaccine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
France Influenza Vaccine Market, 2018-2030 (US$M)
France influenza vaccine market statistics, by vaccine type, 2018-2030 (US$M)
